Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

Inclusion Criteria: * Clinical diagnosis of ocular hypertension, exfoliative open-angle glaucoma, or pigment dispersion glaucoma in at least one eye (study eye). * On a stable IOP (intra-ocular pressure) lowering regimen within 30 days of Screening Visit. * IOP considered safe in both eyes in order to assure clinical stability of vision and optic nerve throughout the study period. * Best corrected visual acuity of 6/60 (20/200 Snellen; 1.0 LogMAR) or better in each eye. * IOP between 19 and 35 mmHG in at least one eye (which would be the study eye) while on brimonidine/timolol fixed combination therapy. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Presence of other primary or secondary glaucoma. * History of ocular herpes simplex. * Any abnormality preventing reliable applanation tonometry. * Corneal dystrophies. * Concurrent infectious/noninfectious conjunctivitis, keratitis, or uveitis in either eye. Blepharitis or non-clinically significant conjunctival injection is allowed. * Intraocular conventional surgery or laser surgery in study eye(s) less than three months prior to Screening Visit. * Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the opinion of the investigator. * Progressive retinal or optic nerve disease from any cause. * Use of systemic medications known to affect IOP which have not been on a stable course for 7 days prior to Screening Visit or an anticipated change in the dosage during the course of the study. * Pregnant or lactating. * Other protocol-defined exclusion criteria may apply.